19 March 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
Publication of Circular
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that further to its 'Fundraising' announcement, published on 17 March 2026 at 7:00 a.m. (the "Fundraising RNS"), a circular convening a General Meeting has today been sent to shareholders.
The General Meeting is scheduled to be held at 11.00 a.m. (GMT) on 7 April 2026, at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.
A copy of the Circular will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.
Terms used but not defined in this announcement have the same meaning as set out in the Fundraising RNS.
For further information, please contact:
|
ImmuPharma PLC (www.immupharma.co.uk.) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations |
+44 (0) 207 206 2650 + 44 (0) 7721 413496 |
|
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin |
+44 (0) 203 368 3550 |
|
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney |
44 (0) 20 3650 3650 |
|
SI Capital (Joint Broker) Nick Emerson |
+44 (0) 1483 413500 |
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.